Los Angeles

Epidemiological Brief

As of 27 July 2026, Los Angeles is classified at LOW epidemic risk (composite score 16.4). Influenza-like illness is the leading signal at 3.9% ILI prevalence (14.1% adjusted), reflecting continued summer influenza activity in California above typical seasonal baseline. Pertussis incidence stands at 1.13 cases per 100,000. COVID-19 activity is modest at 0.55 cases per 100,000. Mpox is detected at 0.11 cases per 100,000, with the adjusted impact attenuated by the mitigation factor. Measles incidence is low at 0.07 cases per 100,000. Travel-associated dengue cases are present at 0.11 cases per 100,000, representing imported infections with limited local vector transmission risk. Wastewater-based epidemiology (ATCP-73RE) is actively monitoring COVID-19 and influenza signals. International arrivals are very high at 14,580 — the second-highest volume in this cycle — substantially increasing multi-pathogen importation risk across all venues. Warm and dry conditions (26 °C, 70% humidity, no precipitation) are typical for summer in Los Angeles. Recommended actions include influenza rapid testing at fan medical posts, MMR and mpox vaccination verification for high-risk incoming travellers, robust dengue prevention messaging, monitoring for pertussis clusters through California DPH channels, and heightened multi-pathogen surveillance across all venues given the very high arrival volumes.

Model SCEME v3.1 · Updated July 27, 2026

Please consult a local doctor or pharmacist for guidance and medication.